AMENDMENT

Please amend the following claims:

1. (amended) A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting an immune response with an immunologically effective amount of a composition comprising a [phosphatidylserine/ polypeptide] lipid or lipid/polypeptide conjugate.

2. (amended) The method of claim 1, wherein said [polypeptide is] immune response is elicited with lipid/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.

11. (amended) The method of claim [8] 7, wherein said lipid is phosphatidylcholine or phosphatidylserine.

Please cancel claims 9-10 and 13-27.

Please add the following claims:

--28. The method of claim 1, wherein said lipid or lipid/polypeptide conjugate is phosphatidylserine or a phosphatidylserine/polypeptide conjugate.

29. The method of claim 3, wherein said ~~animal has~~ cancer.

30. The method of claim ~~29~~, wherein said ~~animal has a tumor~~ cancer cell is comprised within a tumor.

~~31. The method of claim 4, wherein said human has cancer.~~

32. The method of claim ~~31~~, wherein said ~~human has a tumor~~ tumor is within a human.

33. The method of claim ~~32~~, wherein said animal comprises a cancer cell.

34. The method of claim ~~33~~, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.

35. ~~The method of claim 12, wherein said animal has cancer.~~

14 ~~36.~~ The method of claim ~~12~~ 12, wherein said cancer cell is comprised within a tumor ~~animal has a tumor~~.

15 ~~37.~~ The method of claim ~~12~~ 11, wherein said animal is a human.

16 ~~38.~~ The method of claim ~~37~~ 15, wherein said human has cancer.

SUB B4 39. The method of claim 40, wherein said human has a tumor.

A4 18 ~~40.~~ The method of claim ~~12~~ 11, wherein said animal is a mouse.

19 ~~41.~~ The method of claim ~~12~~ 11, wherein said animal is a rat, a hamster, a guinea pig or a goat.

D 20 ~~42.~~ The method of claim ~~12~~ 11, wherein said composition is administered to said animal ~~topically,~~ parenterally, ~~orally,~~ subcutaneously, or by direct injection into a tissue site.

Sub C4 43. The method of claim 12, wherein said immune response is elicited with a lipid or lipid/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.

SUB B6 7 44. The method of claim ~~44~~, wherein said polypeptide is β2-glycoprotein I.--

RESPONSE

A. Status of the Claims

Claims 1-27 were pending at the time of the present action. Of these, claims 9-10 and 13-27 have been canceled. Claims 1, 7 and 11 have been amended. Claims 28-44 have been added. Support for the claims may be found throughout the specification, for example at page 6

A

line 23 through page 11, line 2 and at page 30, lines 29-30. Therefore, claims 1-8, 11-12 and 28-44 are currently pending. The pending claims are reproduced in Appendix A for the Examiner's convenience.

B. Response to Restriction Requirement

In response to the restriction requirement which the Examiner imposed, Applicant elects, without traverse, to prosecute claims 1-8 and 11-12, *i.e.*, the Group I claims.

In the Restriction Requirement, the Examiner stated that the application currently claims multiple inventions and requires restriction to one of five inventions for prosecution at this time. The Examiner asserted that the following inventions were distinguishable: present claims 1-8, 11 and 12 (Group I) drawn to a method of inhibiting cancer cell growth or killing cancer cells; present claim 9-11, 26-27 (Group II) drawn to a method of treating cancer; present claims 13-14 (Group III) drawn to a method of making an antibody; present claims 15-21 (Group IV) drawn to an antibody; and present claims 22-25 (Group V) drawn to a method of detecting phosphatidyl serine. The Examiner argued that restriction was proper because the required unity of invention was lacking between the cited groups.